Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
- Conditions
- Interventions
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT06231680
- Locations
- 🇨🇳
Ying Liu, Zhengzhou, Henan, China
🇨🇳The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06215677
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06196671
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- yue junhan
- Target Recruit Count
- 36
- Registration Number
- NCT06176885
- Locations
- 🇨🇳
Department of Colorectal Surgery, Affiliated Jinhua Hosptial, Zhejiang University, Jinhua, Zhejiang, China
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2023-12-20
- Target Recruit Count
- 46
- Registration Number
- NCT06170697
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06109207
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT06061276
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 244
- Registration Number
- NCT05854849
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 57
- Registration Number
- NCT05825443
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guandong, Guangdong, China
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05821452
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.